Immunic (IMUX) Return on Capital Employed (2014 - 2026)

Immunic has disclosed Return on Capital Employed across 13 years of filings, most recently posting 159.98% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 159.98%, up 182053.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 159.98% (up 182053.0% YoY), and the FY2025 annual result was 5604.13%, down 521822.0% from the prior year.
• Return on Capital Employed came in at 159.98% for Q1 2026 at Immunic, up from 5865.23% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 60.66% in Q1 2022 to a low of 5865.23% in Q4 2025.
• The 5-year median for Return on Capital Employed is 162.24% (2024), against an average of 656.22%.
• Across the five-year window, Return on Capital Employed plunged 554521 bps in 2025 and soared 182053 bps in 2026, its largest moves.
• Immunic's Return on Capital Employed stood at 107.32% in 2022, then tumbled by 157 bps to 276.32% in 2023, then declined by 16 bps to 320.01% in 2024, then slumped by 1733 bps to 5865.23% in 2025, then soared by 97 bps to 159.98% in 2026.
• The last three Return on Capital Employed figures came in at 159.98% (Q1 2026), 5865.23% (Q4 2025), and 502.83% (Q3 2025), per Business Quant data.